News

Santhera's AGAMREE Receives NMPA Approval for DMD Treatment

Santhera's AGAMREE Receives NMPA Approval for DMD Treatment

Santhera Achieves Milestone with AGAMREE Approval in China

Santhera Pharmaceuticals is proud to announce that its drug, AGAMREE® (vamorolone), has received the green light from China’s National Medical Products Administration (NMPA) for the treatment of Duchenne muscular dystrophy (DMD) in children aged four years and older. This significant approval marks AGAMREE as the first and only authorized therapy for DMD in the country, representing a breakthrough for many families affected by this heartbreaking condition.

The Importance of AGAMREE for DMD Treatment

DMD is a rare, inherited disorder that primarily affects boys, leading to progressive muscle degeneration and weakness. Currently, over 70,000 families in China are facing the challenges brought on by this condition, which has historically lacked effective treatment options. With the endorsement of AGAMREE, Santhera’s CEO Dario Eklund expressed optimism: 'This approval allows us to help those suffering from DMD, paving the way for better quality of life for many children in China.' Santhera is eager to collaborate with Sperogenix Therapeutics as they prepare to bring AGAMREE to market.

Collaborative Efforts to Push Forward

Mr. Yan Zhiyu, the Co-founder, Chairman, and CEO of Sperogenix Therapeutics, underscored the significance of this approval, acknowledging the government’s commitment to expedite the development of essential drugs for rare diseases. 'This milestone is a testament to our resolve to address the urgent needs of patient communities,' he emphasized, highlighting the urgency for accessible treatment.

AGAMREE's Unique Mechanism of Action

What sets AGAMREE apart from existing treatments is its unique mechanism of action. Unlike traditional corticosteroids, which often come with significant adverse effects, AGAMREE binds to the same receptor while modifying its downstream activity, thereby reducing safety concerns and potentially dissociating efficacy from steroid-associated side effects. This positions AGAMREE as a promising alternative for managing the condition effectively.

Promising Clinical Trial Results

The pivotal VISION-DMD study demonstrated that AGAMREE achieved key clinical endpoints, with a remarkable improvement in Time to Stand (TTSTAND) velocity compared to placebo. Alongside demonstrating efficacy, AGAMREE maintained a favorable safety profile, reinforcing its potential as a primary treatment option for DMD.

Future Steps for AGAMREE

Santhera operates under an exclusive collaboration with Sperogenix for AGAMREE’s commercialization in China. Following the approval, arrangements are in place for Sperogenix to pay royalties to Santhera, reflecting their shared commitment to advancing DMD treatment. The focus is now on accelerating access and distribution practices to ensure that patients can receive this vital therapy as quickly as possible.

About Santhera Pharmaceuticals

Santhera Pharmaceuticals (SIX: SANN) is dedicated to developing innovative therapies for rare neuromuscular conditions. AGAMREE stands at the forefront of their research initiatives, with the company committed to improving the lives of those affected by DMD. The approval of this therapy in China is a significant step forward in their mission to deliver cutting-edge treatment options.

Frequently Asked Questions

What is AGAMREE?

AGAMREE® (vamorolone) is a novel therapy developed by Santhera Pharmaceuticals for the treatment of Duchenne muscular dystrophy, designed to provide an effective treatment option with reduced safety concerns.

Who is affected by DMD?

Duchenne muscular dystrophy predominantly affects boys and manifests through progressive muscle degeneration, severely impacting mobility and overall health.

What does NMPA approval mean for AGAMREE?

The NMPA approval signifies that AGAMREE is authorized for treatment in patients aged four and older in China, making it the first approved therapy for DMD in the nation.

What are the expected benefits of AGAMREE?

AGAMREE aims to improve muscle function in DMD patients while minimizing side effects commonly associated with traditional steroid treatments, providing a new hope for better management of the disease.

How can patients access AGAMREE?

After its commercial launch, patients can access AGAMREE through medical channels established by Sperogenix Therapeutics in China, with further information to be announced as the product rolls out.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 99

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 631

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 514

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 446

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing in Kinross Gold: A Decade of Growth Analysis

Updated Category News Views 173

Investing in Kinross Gold: A Decade of Growth Kinross Gold (NYSE: KGC), an influential player in the mining industry, has showcased a remarkable performance over the past decade. With an impressive annualized return of 28.15% that exceeds market benchmarks by 15.29%, investors have much to consider regarding the potential of this gold mining giant. The Impact of...

Continue Reading
Chagee Holdings Limited Reports Robust Financial Growth in Q2 2025

Updated Category News Views 391

Chagee Holdings Limited Shows Impressive Growth in Q2 2025 Chagee Holdings Limited (NASDAQ: CHA), a prominent player in the premium tea drinks sector, has reported impressive unaudited financial results for the second quarter of the financial year. The company, renowned for its innovative approach to freshly-made tea drinks, has made significant strides as it continues to...

Continue Reading
Recent Notification on Major Holdings of RENEWI PLC

Updated Category News Views 149

Understanding Major Holdings in RENEWI PLC Investors and stakeholders often seek clarity on significant holdings within companies. This not only shapes perceptions but also influences future decisions and strategies. RENEWI PLC has recently documented changes regarding its holdings and the requirements for notifying stakeholders. This disclosure is crucial for those...

Continue Reading
Gold Port Corporation Expands Private Placement Funding

Updated Category News Views 244

Gold Port Corporation Increases Private Placement to Meet Demand Gold Port Corporation (CSE: GPO) is excited to announce an increase in its non-brokered private placement as a response to significant investor interest. Originally set to raise $1,500,000 through the sale of 20,000,000 units at a price of $0.075 per unit, the company is now keen on maximizing this...

Continue Reading
Ensemble Enhances Patient Care with Strategic Partnership

Updated Category News Views 83

Ensemble made headlines by teaming up with Mary Washington Healthcare (MWHC) in a move that was supposed to revolutionize healthcare services. Back then, the talk was all about boosting financial performance and enhancing patient experiences through some fancy technology. Traders kept an eye on this partnership, pondering whether it could be more than just corporate...

Continue Reading